Stay updated on Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Sign up to get notified when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.

Latest updates to the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page
- Check4 days agoChange DetectedAdded a dedicated Locations section with regional site listings (Arizona, California, Florida, Tennessee, Texas, Alberta, and Quebec) and replaced the previous location blocks. The HHS Vulnerability Disclosure link was removed in this update.SummaryDifference0.8%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision: v3.3.2 was implemented, replacing the previous v3.3.1. This is a minor maintenance update that does not modify any study details, eligibility criteria, or results displayed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedThe Publications section text was updated from 'about the study results' to 'about the results of the study,' and a new 'Revision: v3.3.1' label was added.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page no longer shows a government funding status notice. This administrative banner did not affect study details or results.SummaryDifference0.3%

- Check54 days agoChange DetectedNo significant changes to core study details were detected; only minor textual or formatting edits appear in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange DetectedUpdated operating-status notice and version to v3.2.0, replacing v3.1.0; core content now includes government funding status and NIH Clinical Center operating details.SummaryDifference2%

Stay in the know with updates to Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.